Navigation Links
Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease
Date:12/3/2010

safety, tolerability and statistically significant effects on a biomarker of disease progression in ALS.  Neuraltus is committed to accelerating the development of new drug molecules based on novel biology and representing first-in-class approaches to target indications in neurodegenerative disease where there is substantial unmet medical need.

About Neuraltus Pharmaceuticals, Inc.

Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases.  Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), Parkinson's disease and dyskinesias associated with the treatment of Parkinson's disease, Alzheimer's disease, and Multiple Sclerosis, as well as lysosomal storage disorders such as Fabry's disease and Gaucher's disease.  Each of Neuraltus' clinical-stage programs is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company's target disease indications.

Neuraltus began operations in 2009 based on a broadly enabling technology portfolio and intellectual property assembled by the company founders, Ari Azhir, PhD, Neuraltus' Chief Operating Officer; Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco; and Edgar Engleman, MD, Professor of Medicine and Pathology at Stanford University School of Medicine.  In March 2009 Neuraltus closed a $17M Series A financing with leading venture groups Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

For more information on Neuraltus, please visit www.neuraltus.com.


'/>"/>
SOURCE Neuraltus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
2. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
3. Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection
4. Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP
5. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
6. Onyx Pharmaceuticals Announces December 2010 Investor Events
7. Endo Pharmaceuticals Holdings Inc. Announces Pricing of Private Offering of Senior Notes
8. Prolong Pharmaceuticals Boosts Executive Team
9. Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection
10. Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
11. Fast Forward, LLC and Provid Pharmaceuticals Announce Expansion of their Partnership for the Development of PV-267, Provids Unique MS Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... MIAMI LAKES, Fla. , May 17, 2013 ... products and delivery technology company that is developing new, patent-pending ... and minerals, announced today that it will hold a business ... on Wednesday, May 22 nd , 2013 at 4:30 PM ... Brian Tuffin will host the call and will ...
(Date:5/17/2013)... JERUSALEM , May 17, 2013 ... a developer of oral drug delivery systems, announced today ... has cleared the Company,s Investigational New Drug application(IND) for ... very pleased to have the FDA clearance to proceed," ... Oramed. "The upcoming trial is a major milestone for ...
(Date:5/16/2013)... , May 16, 2013  PTC Therapeutics, Inc., today ... Form S-1 with the U.S. Securities and Exchange Commission ... its common stock. The number of shares to be ... not been determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ... acting as joint book-running managers for the offering. Cowen ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
(Date:5/19/2013)... 2013 Americans live closer to their ... American Veterinary Medical Association (AVMA) U.S. Pet Ownership and ... consider their dog a member of the family, up ... much five years earlier. , According to the American ... national income dedicated to pets has increased every year ...
(Date:5/19/2013)... May 19, 2013 Yeast infections are common ... in sensitive areas of the human body. A new yeast ... new formula provides a unique method of application to help ... solution is now provided to men and women searching for ... absorbed in the body through food and is stored in ...
(Date:5/19/2013)... Buenos Aires, Argentina: Yoga classes ( clases de ... Argentina by the Sivananda Yoga Vedanta Center. The ... (Barrio Norte). Classes are 90 minutes and are offered ... in a calm environment, allowing visitors to enjoy the ... food, among others. , The Yoga classes follow the ...
(Date:5/19/2013)... 19, 2013 The Da Vinci robot ... developments in the nation’s first trial involving a Da ... Washington State Superior Court, was filed by the widow ... suffered complications in a robot-assisted prostate removal, according to ... Vinci robotic surgery lawsuit alleges those complication’s hastened ...
(Date:5/18/2013)... 2013) Each year, the American Gastroenterological Association ... and achievements in gastroenterology through its esteemed recognition ... and talented individuals who work tirelessly to advance ... are pleased to announce the 2013 recognition award ... for their tremendous contributions to our field," said ...
Breaking Medicine News(10 mins):Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 4Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 3Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 4Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 5
... has been found that elders in hospitals and care homes are ... this, many of them are said to be in hunger// for ... Ivan Lewis. ,Commencing the ‘Dignity for older people’ campaign ... people should be thoroughly understood. When the food is kept far ...
... Pennsylvania School of Medicine have described a new type ... the patient's thoughts, providing two-way signaling for motor control ... at a junction now of developing a new approach ... Smith, MD, Professor of Neurosurgery and Director of the ...
... Scientists have unlocked the secrets of a deadly superbug that attacks ... ,The news is a vital first step in attempts to ... resistant to current antibiotic treatments. ,Already responsible for ... stages of an epidemic that could result in a massive death ...
... study, published in the March 1, 2007 issue of CANCER, ... termination of this highly effective breast cancer drug may negatively ... that over one third of women have ceased tamoxifen treatment. ... quarter of women treated for breast cancer stop tamoxifen within ...
... traits shape up in natural populations,// but one is led ... Two theories have tried to address this challenge – the ... ,The theory of hitchhiking has indicated that genes ... in natural populations when they "hitch a ride" with healthier ...
... whatever the color”, says Dr.Clive Anderson, consultant dermatologist and ... address is part of a move to get Jamaicans ... of the island’s youth resort to bleaching or lightening ... ,Government health officials plan to launch a ...
Cached Medicine News:Health News:New Ideas on Developing Thought-Controlled Artificial Limbs 2Health News:Tamoxifen Discontinuation Rates Surprisingly High 2Health News:The Evolution of Costly Traits 2
... an innovative, quick and easy automated ... 60% less space on your laboratory ... this amazingly easy-to-use, one-hand system, you ... whole range of Diamond Tips. All ...
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
For the quantitative determination of luteinizing hormone (LH) concentration in human serum....
Medicine Products: